A detailed history of Jpmorgan Chase & CO transactions in Hutchmed (China) LTD stock. As of the latest transaction made, Jpmorgan Chase & CO holds 49 shares of HCM stock, worth $853. This represents 0.0% of its overall portfolio holdings.

Number of Shares
49
Previous 318 84.59%
Holding current value
$853
Previous $5,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

SELL
$16.03 - $20.31 $4,312 - $5,463
-269 Reduced 84.59%
49 $0
Q2 2024

Aug 12, 2024

SELL
$16.36 - $21.78 $57,112 - $76,033
-3,491 Reduced 91.65%
318 $5,000
Q1 2024

May 10, 2024

BUY
$12.08 - $18.56 $17,781 - $27,320
1,472 Added 62.99%
3,809 $63,000
Q4 2023

Feb 12, 2024

BUY
$16.25 - $20.23 $48 - $60
3 Added 0.13%
2,337 $42,000
Q3 2023

Nov 14, 2023

SELL
$11.85 - $16.95 $75,531 - $108,039
-6,374 Reduced 73.2%
2,334 $39,000
Q2 2023

Aug 11, 2023

SELL
$10.78 - $17.73 $94,766 - $155,864
-8,791 Reduced 50.24%
8,708 $104,000
Q1 2023

May 11, 2023

SELL
$13.02 - $19.87 $71,649 - $109,344
-5,503 Reduced 23.92%
17,499 $227,000
Q4 2022

Feb 13, 2023

SELL
$7.65 - $15.51 $1.8 Million - $3.66 Million
-235,703 Reduced 91.11%
23,002 $340,000
Q3 2022

Nov 14, 2022

SELL
$8.63 - $15.52 $221,135 - $397,684
-25,624 Reduced 9.01%
258,705 $2.29 Million
Q2 2022

Aug 11, 2022

SELL
$8.59 - $20.77 $1.11 Million - $2.68 Million
-129,120 Reduced 31.23%
284,329 $3.59 Million
Q1 2022

May 11, 2022

SELL
$15.52 - $35.65 $17 Million - $39.1 Million
-1,096,384 Reduced 72.62%
413,449 $7.82 Million
Q4 2021

Feb 10, 2022

SELL
$28.89 - $35.33 $4.71 Million - $5.76 Million
-162,945 Reduced 9.74%
1,509,833 $53 Million
Q3 2021

Nov 12, 2021

BUY
$35.66 - $42.94 $59.7 Million - $71.8 Million
1,672,778 New
1,672,778 $61.2 Million

Others Institutions Holding HCM

About HUTCHMED (China) Ltd


  • Ticker HCM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 172,955,008
  • Market Cap $3.01B
  • Description
  • HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...
More about HCM
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.